Algenex raises €7.4 million C round, looks to partner manufacturing platform with COVID-19 vaccine developers

Algenex’s latest financing will allow the Spanish biotech to ramp up its Baculovirus manufacturing technology, which could provide a cheaper and faster platform for producing vaccine antigens.

On Tuesday Algenex S.L. raised €7.4 million ($8.8 million) in a series C round led by MasterLux with participation from Columbus Life Science Fund II, a fund managed by Columbus Venture Partners, and other undisclosed private investors...